Pepgen announces presentations at the 2023 myotonic dystrophy foundation annual conference, ottawa neuromuscular disease meeting, and h.c. wainwright 25th annual global investment conference

Boston, sept. 01, 2023 (globe newswire) -- pepgen inc. (nasdaq: pepg), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it will be presenting at upcoming medical meetings and an investor conference. ashling holland, director of preclinical development at pepgen, will be giving a talk titled “pgn-edodm1 nonclinical data demonstrated mechanistic and meaningful activity for the potential treatment of myotonic dystrophy type 1 (dm1)”, at the 2023 myotonic dystrophy foundation annual conference, on september 9, 2023, in washington, d.c.
PEPG Ratings Summary
PEPG Quant Ranking